[1]吴亚东,史晓林,晁振宇.福善美对绝经后骨质疏松症患者 血清骨保护素及骨密度的影响[J].中医正骨,2011,23(06):16-20.
　WU Ya-dong*,SHI Xiao-lin,CHAO Zhen-yu.*.Effect of Fosamax on serum osteoprotegerin and bone density in patients with postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(06):16-20.
点击复制

福善美对绝经后骨质疏松症患者 血清骨保护素及骨密度的影响()
分享到：

《中医正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第23卷
期数:
2011年06期
页码:
16-20
栏目:
临床研究
出版日期:
2011-06-30

文章信息/Info

Title:
Effect of Fosamax on serum osteoprotegerin and bone density in patients with postmenopausal osteoporosis
作者:
吴亚东1; 史晓林2; 晁振宇3
1.浙江中医药大学2008级硕士研究生,浙江 杭州 310053;
2.浙江中医药大学第二 附属医院,浙江 杭州 310005;
3.山东省菏泽市中医医院,山东 菏泽 274000
Author(s):
WU Ya-dong*; SHI Xiao-lin; CHAO Zhen-yu.*
2008 Ph.D. candidate of Zhejiang University of Chinese Medicine,Hangzhou 310053,Zhejiang,China
关键词:
骨质疏松; 绝经后 二膦酸盐类 骨密度 骨保护素
Keywords:
Osteoporosis; Postmenopausal;  Diphosphonates;  Bone density;  Osteoprotegerin
摘要:
目的:观察福善美对绝经后骨质疏松症患者血清骨保护素水平及骨密度的影响,进一步探讨福善美治疗绝经后骨质疏松症的机理。方法:将符合要求的82例患者随机分为2组,治疗组42例,对照组40例。治疗组患者口服福善美、阿法迪三及钙尔奇D; 对照组患者口服阿法迪三和钙尔奇D。分别于治疗前、治疗6个月、治疗12个月时测定患者的血清骨保护素水平和骨密度。结果:①2组之间血清骨保护素水平比较,差异有统计学意义(F=4.793,P=0.031)。时间因素与处理方法存在交互效应(F=90.608,P=0.000)。不同的时间点之间存在时间效应(F=48.717,P=0.000); 治疗组治疗6个月及治疗12个月时血清骨保护素水平低于治疗前(P=0.000,P=0.000); 对照组治疗6个月及治疗12个月时血清骨保护素水平与治疗前相比,差异无统计学意义(P=0.375,P=0.120)。治疗组血清骨保护素水平呈逐渐下降趋势,而对照组无显著变化。②2组之间骨密度比较,差异有统计学意义(F=4.092,P=0.046)。时间因素与处理方法存在交互效应(F=48.361,P=0.000)。不同的时间点之间存在时间效应(F=29.826,P=0.000); 治疗组治疗6个月及治疗12个月时骨密度高于治疗前(P=0.000,P=0.000); 对照组治疗6个月及治疗12个月时骨密度与治疗前相比,差异无统计学意义(P=1.000,P=0.830)。治疗组骨密度呈逐渐升高趋势,而对照组无显著变化。结论:福善美可降低绝经后骨质疏松患者血清骨保护素水平,明显增加骨密度。福善美治疗绝经后骨质疏松症的机理可能是它能直接和间接抑制破骨细胞活性。
Abstract:
Objective:To observe the effect of Fosamax on serum osteoprotegerin level and bone density in patients with postmenopausal osteoporosis,and make further study on the mechanism of Fosamax in the treatment of postmenopausal osteoporosis.Methods:82 patients met the criterion were randomly divided into 2 groups,42 cases in the treatment group,while the others in the control group.Patients in the treatment group were administrated with Fosamax,Alpha D3 and Caltrate D,while the others in the control group were administrated with Alpha D3 and Caltrate D only.Serum osteoprotegerin level and bone density of the patients were measured before the treatment,after treatment for 6 months and 12 months respectively.Results:①There was statistical difference in the serum osteoprotegerin level between the 2 groups(F=4.793,P=0.031),and there was interaction effects between time factor and treatment process(F=90.608,P=0.000).There was time effects between different time(F=48.717,P=0.000).For the patients in the treatment group,serum osteoprotegerin levels after treatment for 6 months and 12 months were lower than those before the treatment(P=0.000,P=0.000).For the patients in the control group,there was no statistical difference in the serum osteoprotegerin levels between the 6th month,12th month after the treatment and before the treatment(P=0.375,P=0.120).Serum osteoprotegerin levels of patients reduced significantly in the treatment group,compared with no significant changes of those in the control group.②There was statistical difference in the bone density between the 2 groups(F=4.092,P=0.046),and there was interaction effects between time factor and treatment process(F=48.361,P=0.000).There was time effects between different time(F=29.826,P=0.000).For the patients in the treatment group,bone density after treatment for 6 months and 12 months were higher than those before the treatment(P=0.000,P=0.000).For the control group,there was no statistical difference in the bone density between the 6th month,12th month after the treatment and before the treatment(P=1.000,P=0.830).Bone density of patients increased gradually in the treatment group,compared with no significant changes of those in the control group.Conclusion:Fosamax can increase bone density obviously and reduce the levels of serum osteoprotegerin in the patients with postmenopausal osteoporosis,and its treatment mechanism maybe rely on the direct and indirect inhibition of osteoclast activity.

参考文献/References:

[1] Epstein S.Update of current therapeutic options for the treatment of postmenopausal osteoporosis[J].Clin Ther,2006,28(2):151-173.
[2] 刘忠厚.骨矿与临床[M].北京:中国科学出版社,2006:531.
[3] 孟迅吾,朱汉民,刘建立,等.阿仑膦酸钠治疗绝经后骨质疏松症的疗效和耐受性[J].基础医学与临床,2007,27(2):174-177.
[4] 陈瑾瑜,盛正妍,游利,等.不同药物治疗女性绝经后骨质疏松的近期疗效观察[J].中华老年医学杂志,2007,26(10):770-771.
[5] 刘忠厚,杨定焯,朱汉民,等.中国人原发性骨质疏松症诊断标准(试行)[J].中国骨质疏松杂志,1999,5(1):1-3.
[6] 孙文利,周迪军,谢辉,等.护骨素与女性年龄和骨密度的关系[J].中国骨质疏松志,2008,14(7):467-470.
[7] Fahrleitner-Pammer A,Dobnig H,Piswanger-Soelkner C,et al.Osteoprotegerin serum levels in women:correlation with age,bone mass,bone turnover and fracture status[J].Wien Klin Wochenschr,2003,115(9):291-297.
[8] Dai Y,Shen L.Relationships between serum osteoprotegerin,matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women[J].Chin Med J(Engl),2007,120(22):2017-2021.
[9] 梁少俊,刘宏,杨力,等.绝经后骨质疏松与血清OPG及RANKL关系的研究[J].广东医学,2006,27(5):669-671.
[10] 张良岩,丛琳,杨乃龙,等.利塞膦酸钠对绝经后骨质疏松症患者BMD、血清OPG和TNF-α的影响[J].山东医药,2005,45(25):33-34.
[11] Hofbauer LC,Kühne CA,Viereck V.The OPG/RANKL/RANK system in metabolic bone diseases[J].J Musculoskelet Neuronal Interact,2004,4(3):268-275.
[12] 戴燚,沈霖.绝经后妇女血清骨保护蛋白和基质金属蛋白酶-2水平与骨密度和骨代谢指标的关系[J].中国中医骨伤科杂志,2007,15(2):35-39.
[13] Fahrleitner-Pammer A,Dobnig H,Piswanger-Soelkner C,et al.Osteoprotegerin serum levels in women:correlation with age,bone mass,bone turnover and fracture status[J].Wien Klin Wochenschr,2003,115(9):291-297.
[14] 陆敬辉,张浩,黄琪仁,等.福善美对绝经后妇女骨密度的影响[J].中国骨质疏松杂志,2005,11(1):85-87.
[15] 周玲霞.福善美治疗绝经后妇女骨质疏松症的观察和护理[J].现代中西医结合杂志,2007,16(20):2927-2928.
[16] Reyes-García R,Muñoz-Torres M,García DF,et al.Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis[J].Menopause,2010,17(1):140-144.

相似文献/References:

[1]李林军.应用膨胀式椎弓根螺钉内固定治疗合并骨质疏松的 胸腰椎退行性疾病[J].中医正骨,2015,27(08):49.
[2]韩艳,温利平,刘娜,等.补肾活血方对去卵巢大鼠骨代谢及骨密度的影响[J].中医正骨,2015,27(12):7.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(补肾活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(06):7.
[3]李学朋,朱立国.骨疏康胶囊对去卵巢大鼠骨小梁的影响[J].中医正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康胶囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(06):12.
[4]陈冠军,陈扬,庄汝杰.可灌注骨水泥椎弓根螺钉系统 在老年腰椎疾患手术中的应用[J].中医正骨,2015,27(02):40.
[5]王丹辉,贲越,韩梅.林蛙油治疗绝经后骨质疏松症的临床研究[J].中医正骨,2014,26(01):27.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(06):27.
[6]黄建华,黄建武,李慧辉,等.加味左归丸对绝经后骨质疏松症肝肾不足证 患者骨密度的影响[J].中医正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(06):19.
[7]项旻,杨虹,林爱菊,等.绝经后2型糖尿病患者骨质疏松与血微量元素的关系研究[J].中医正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(06):20.
[8]史晓林,李春雯,张志强.弱阳离子磁珠分离技术和基质辅助激光解吸电离飞行时间质谱技术在原发性Ⅰ型骨质疏松症血清标志蛋白筛选中的应用[J].中医正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(06):5.
[9]李明,徐明雄,冯左基,等.自拟壮骨方治疗绝经后骨质疏松症的疗效及作用机制研究[J].中医正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(06):21.
[10]陈俊杰,李晴晴,夏瑢.脂代谢及血清内脂素水平与绝经后骨质疏松症的 相关性研究[J].中医正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(06):16.

备注/Memo

备注/Memo:
基金项目:浙江省中医管理局中医(中西医结合)单病种诊疗规范研究项目(2008GA014)
通讯作者:史晓林 E-mail:xlshi-2002@163.com
更新日期/Last Update: 2011-06-30